Canada markets closed

Sona Nanotech Inc. (SONA.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.4150-0.0550 (-11.70%)
At close: 03:59PM EDT
Full screen
Previous Close0.4700
Open0.5500
Bid0.4100 x 0
Ask0.4300 x 0
Day's Range0.4150 - 0.5600
52 Week Range0.1350 - 0.5600
Volume761,929
Avg. Volume74,115
Market Cap41.145M
Beta (5Y Monthly)-1.67
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

    Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). The Company was provided with data from the Study that indicates the response in a pre-clinical triple negative breast cancer model treated with the combination of Sona's targeted hyperthermia therapy ("THT

  • Newsfile

    Sona Nanotech Secures Grant Funding to Support Intellectual Property Strategy and Development

    Halifax, Nova Scotia--(Newsfile Corp. - April 8, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces that it has been approved for funding totaling approximately $40,000 to support the development of its intellectual property portfolio. The Company is receiving advisory services and up to $24,894 in funding from the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") IP Assist program to support the development of ...

  • Newsfile

    Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results

    Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). An update received by the Company indicates that all tumors treated within the Study to date with a single Targeted Hyperthermia Therapy ("THT") treatment shrunk within the first 24 hours, with an average reduction in ...